Triumvira Immunologics
Phase 1/2Our proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.
Founded
2015
Focus
Cell & Gene Therapy
About
Our proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.
Funding History
2Total raised: $155M
Series B$100MGilead SciencesOct 15, 2023
Series A$55MLeaps by BayerMar 15, 2021
Company Info
TypePrivate
Founded2015
LocationAustin, United States
StagePhase 1/2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile